Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333817 | 0.85 | NLRP3 (0.52) | EPHX1MAPTCDK8SMN1; SMN2 | |
| SCHEMBL21788373 | 0.85 | EPHX2 (0.52) | EPHX1ALDH1A1EPHX2GAAHPGD | |
| SCHEMBL1490960 | 0.82 | EPHX1 (0.59) | EPHX1ALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL21788391 | 0.82 | EPHX2 (0.57) | EPHX1ALDH1A1HTTEPHX2HPGD | |
| SCHEMBL10192072 | 0.81 | MEN1 (0.69) | EPHX1ALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL6064818 | 0.81 | EPHX1 (0.66) | EPHX1ALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL6438910 | 0.81 | EPHX1 (0.83) | EPHX1ALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL27406518 | 0.80 | EPHX1 (0.64) | EPHX1ALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL4602668 | 0.79 | LPL (0.53) | ALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL23169416 | 0.79 | LMNA (0.58) | ALDH1A1EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616071-A2 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | EPHX1 1348/4885ALDH1A1 671/4885HTT 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.